The Priority Review

Tag

Novo Nordisk

1 story

  1. Clinical trials

    Novo Nordisk posts results of Phase 3 semaglutide trial in HFpEF with diabetes

    The company posted results of a completed Phase 3 study that enrolled 617 participants with heart failure with preserved ejection fraction and type 2 diabetes, comparing semaglutide 2.4 mg once-weekly to a dummy medicine. The trial began on June 15 2021 and reached primary completion on October 11 2023.